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Background: One of the major components of telomerase is the human telomerase reverse transcriptase (hTERT)
as the catalytic protein. hTERT mRNA expression are reported to be associated with prognosis and tumor
progression in several sarcomas. However, there is no clear understanding of the mechanisms of hTERT in human
sarcomas. Recent studies have suggested that signals transmitted through p38 mitogen-activated protein kinase
(MAPK) can increase or decrease hTERT transcription in human cells. The purpose of this study was to analyse the
correlation between p38 MAPK and hTERT in sarcoma samples.
Methods: We investigated 36 soft tissue malignant fibrous histiocytomas (MFH), 24 liposarcomas (LS) and 9 bone
MFH samples for hTERT and p38 MAPK expression. Quantitative detection of hTERT and p38 MAPK was performed
by RT-PCR.
Results: There was a significant positive correlation between the values of hTERT and p38 MAPK in all samples (r =
0.445, p = 0.0001), soft tissue MFH (r = 0.352, p = 0.0352), LS (r = 0.704, p = 0.0001) and bone MFH samples (r =
0.802, p = 0.0093). Patients who had a higher than average expression of p38 MAPK had a significantly worse
prognosis than other patients (p = 0.0036).
Conclusions: p38 MAPK may play a role in up-regulation of hTERT, and therefore, p38 MAPK may be a useful
marker in the assessment of hTERT and patients’ prognosis in sarcomas.
Keywords: p38 mitogen-activated protein kinase, human telomerase reverse transcriptase, malignant fibrous histio-
cytoma, liposarcoma
Background
Telomerase, an enzyme related to cellular immortality,
stabilizes telomere length by adding DNA repeats onto
telomere ends [1,2]. Many studies have revealed that tel-
omerase activity is expressed in many different types of
carcinomas, detected in more than 85% of the human
carcinoma samples, and it has been found to be useful
as a prognostic indicator [3-5]. Telomerase activity is
mainly regulated by human telomerase reverse tran-
scriptase (hTERT), which is the catalytic subunit of
telomerase [6,7]. Also, hTERT has been significantly
detected in many types of sarcoma samples, and pre-
vious reports have indicated that hTERT expression is
associated with tumor aggressiveness, feature and clini-
cal outcome in sarcomas [8-14]. Therefore, hTERT may
play an important role in telomere maintenance
mechanisms in human sarcomas. However, it is notable
that thus far, there has been no clear understanding of
the mechanisms of hTERT expression especially in sar-
comas. p38 is a mitogen-activated protein kinase
(MAPK) activated by phosphorylation on serine/threo-
nine residue when cells are exposed to cellular stress,
and has a wide variety of biological functions [15-17].
Recent studies have suggested that signals transmitted
through MAP kinase can increase or decrease hTERT
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on the downstream mediators [18-22]. This study was
undertaken to analyze the clinical significance of p38
MAPK and hTERT expression in primary tumor sam-
ples from soft tissue malignant fibrous histiocytomas
(MFH), liposarcomas (LS) and bone MFH patients. In
addition, with the broader aim of discovering regulation
factors of hTERT in sarcomas, we investigated whether
there is a correlation between hTERT and p38 MAPK.
Methods
Patients and tumor samples
A total of 69 (36 soft tissue MFHs, 24 LSs and 9 bone
MFHs) sarcoma samples were obtained at the time of
surgery, were immediately frozen and stored at -80°C
until commencement of our study. Summarized clinical
data at the time of last observation are shown in Tables
1, 2 and 3. All patients with these sarcomas were treated
with tumor resection and/or chemotherapy between
1988 and 2005. We performed brachytherapy or exter-
nal radiation therapy following conservative surgery for
all soft tissue sarcoma patients who received marginal
resection. Chemotherapy comprised of multiagent sys-
temic chemotherapy in metastatic patients. High dose
ifosfamide, doxorubicin and/or cisplatin were used. We
collected all primary tumor samples by tumor resection
or biopsy, and no patients had undergone chemotherapy
before surgical specimens were collected. The study was
approved by our institutional review board (Dai eki 133,
and 263).
Quantification of hTERTand p38 MAPK mRNA expression
Total cellular RNA was extracted using a Rneasy Mini
Kit (Qiagen, Valencia, CA), and cDNA was synthesized
using 1 μg of total RNA using a Transcriptor First
Strand cDNA Synthesis Kit (Roche Applied Science,
Mannheim, Germany). Quantitative detection of hTERT
mRNA and p38 MAPK was performed with the Light-
Cycler TaqMan Master using the LightCycler instru-
ment (Roche Molecular System, Alameda, CA). The
primer pairs 5’-CGGAAGAGTGTCTGGAGCAA-3’ and
5’-GGATGAAGCGGAGTCTGGA-3’ for hTERT, and
5’-ATGCCGAAGATGAACTTTGC-3’ and 5’-
TCTTATCTGAGTCCAATACAAGCATC-3’ for p38
MAPK were used for amplification. PCR used 10 sec-
onds at 95°C, 30 seconds at 60°C and 1 second at 72°C
with 45 cycles. Expression of the gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was also analyzed
in each tumor sample as an indicator of RNA quality. A
3×1 0
6 of HeLa cell was used as a positive control.
Quantification of mRNA expression was indicated by
measuring mRNA expression levels of hTERT or p38
MAPK/mRNA levels of the Hela cell ratio.
Statistical analysis
The cumulative prospective of overall survival was calcu-
lated using the method of Kaplan-Meier. Statistical signifi-
cance of the differences between the survival curves was
evaluated using the log-rank test. Pearson’sp r o d u c t -
moment correlation coefficient (r and p values) was used
to study the relationship between p38 MAPK and hTERT.
Data are presented as the mean ± SD. In all analyses, a p
value of < 0.05 was considered to indicate significance.
Results
Overall results of 69 samples
p38 MAPK and hTERT mRNA expression
p38 MAPK expression was demonstrated in 84.1% (58
of 69) and hTERT mRNA expression was demonstrated
in 91.3% (63 of 69) of all 69 samples. The levels of p38
MAPK were 13.4 ± 27.7 (range: 0-191.1) and those of
hTERT were 336.5 ± 554.8 (range: 0-2656.0) in all sam-
ples. We previously reported the data of hTERT in bone
and soft tissue MFHs [23,24].
Correlation between levels of p38 MAPK and hTERT mRNA
expression
There was a significant correlation between the values of
p38 MAPK expression and hTERT, with increased p38
MAPK expression with higher hTERT in all samples (r
= 0.445, p = 0.0001) (Figure 1).
Prognostic factors
Patients who had a higher than average expression of
p38 MAPK had a significantly worse prognosis (5-year
survival rate; 38.1%) than other patients overall (73.8%)
(p = 0.0036) (Figure 2). There were no significant differ-
ences in prognosis between patients who had a higher
than average expression of hTERT (5-year survival rate:
38.6%) and those who did not (71.1%) (p = 0.0585).
Soft tissue MFH samples
p38 MAPK and hTERT mRNA expression
p38 MAPK expression was demonstrated in 77.8% (28
of 36) and hTERT mRNA expression was demonstrated
in 88.9% (32 of 36) of soft tissue MFH samples. The
levels of p38 MAPK were 9.60 ± 17.5 (range: 0-71.1)
and those of hTERT were 371.6 ± 695.9 (range: 0-
2656.0).
Correlation between levels of p38 MAPK and hTERT mRNA
expression
There was a significant correlation between the values of
p38 MAPK expression and hTERT, with increased p38
MAPK expression with higher hTERT in soft tissue
MFH samples (r = 0.352, p = 0.0352) (Figure 3).
Prognostic factors
There were no significant differences in prognosis
between patients who had a higher than average expres-
sion of p38 MAPK (5-year survival rate: 41.7%) and
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significant differences in prognosis between patients
who had a higher than average expression of hTERT
(41.7%) and those who did not (62.7%) (p = 0.610).
Liposarcoma samples
p38 MAPK and hTERT mRNA expression
p38 MAPK expression was demonstrated in 95.8% (23
of 24) and hTERT mRNA expression was demonstrated
in 91.7% (22 of 24) of LS samples. The levels of p38
MAPK were 6.81 ± 11.5 (range: 0-38.2) and those of
hTERT were 171.3 ± 189.9 (range: 0-726.6) in LS
samples.
Correlation between levels of p38 MAPK and hTERT mRNA
expression
There was a significant correlation between the values of
p38 MAPK expression and hTERT, with increased p38
MAPK expression with higher hTERT in LS samples (r
= 0.704, p = 0.0001) (Figure 4).
Prognostic factors
Patients who had a higher than average expression of
p38 MAPK (5-year survival rate: 50.0%) had a
Table 1 Data in 36 patients with soft tissue MFH
Age (Yrs) Gender Site Histol. Type Prognosis Period (mos.) hTERT p38
53 Male thigh stori-pleo DOD 12 28.4 0
48 Male thigh myxoid NED 80 1564.5 0
76 Female thigh stori-pleo DOD 22 2365 8.7
54 Male thigh stori-pleo DOD 12 978.4 6.1
49 Male upper arm stori-pleo DOD 18 22 2.8
63 Female axillary myxoid CDF 28 383.4 4.5
82 Male thigh stori-pleo CDF 80 181.9 3.3
66 Female thigh stori-pleo CDF 60 133.2 0
75 Male thigh stori-pleo NED 35 1986.5 2.8
45 Female inguinal myxoid CDF 27 8.5 0.3
78 Female thigh stori-pleo DOD 9 8.9 5.2
35 Male thigh stori-pleo CDF 52 1.9 2.1
81 Male thigh stori-pleo CDF 26 0 0
84 Male buttock stori-pleo CDF 26 45.9 10
57 Female shoulder stori-pleo CDF 62 158.3 36.2
76 Female thigh stori-pleo DOD 6 196.8 50.1
75 Male thigh stori-pleo DOD 10 147.3 15.6
57 Male thigh stori-pleo CDF 94 696.5 14.1
69 Male thigh stori-pleo CDF 94 18 60.3
72 Male thigh stori-pleo DOD 49 0 0.3
64 Female buttock myxoid DOD 10 2.6 10.3
55 Female thigh myxoid DOD 21 1029.5 23
59 Female shoulder stori-pleo DOD 47 2656 71.1
74 Male thigh myxoid DOD 27 15.6 0.4
59 Female lower leg inflammatory CDF 115 4.6 1.7
46 Male thigh stori-pleo CDF 98 0 0
73 Male thigh stori-pleo CDF 112 0 0
62 Female forearm myxoid CDF 138 145.3 5
59 Female thigh stori-pleo DOD 7 45.3 1.3
49 Male upper arm stori-pleo CDF 87 10.1 0
85 Male thigh stori-pleo CDF 106 0.9 0.2
58 Female buttock stori-pleo DOD 6 103.8 0.1
73 Male thigh stori-pleo CDF 112 145.3 0
78 Male lower leg stori-pleo CDF 119 125.1 0.2
71 Female lower leg myxoid NED 65 31.9 2.4
73 Female lower leg myxoid CDF 25 135.6 7.8
stori-pleo = storiform-pleomorphic type
CDF = continuously disease-free
NED = no evidence of disease
DOD = died of disease
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(p = 0.0448) in LS patients. There were no significant
differences in prognosis between patients who had a
higher than average expression of hTERT (62.5%) and
those who did not (87.5%) (p = 0.110).
Bone MFH samples
p38 MAPK and hTERT mRNA expression
p38 MAPK expression was demonstrated in 77.8% (7 of
9) and hTERT expression was demonstrated in all (9 of
9) of bone MFH samples. The levels of p38 MAPK were
46.4 ± 58.2 (range: 0-191) and the levels of hTERT were
636.5 ± 453.3 (range: 241.7-1405.4) in bone MFH
samples.
Correlation between levels of p38 MAPK and hTERT mRNA
expression
There was a significant correlation between the values of
p38 MAPK expression and hTERT, with increased p38
MAPK expression with higher hTERT (r = 0.802, p =
0.0093) (Figure 5).
Table 2 Data in 24 patients with liposarcoma
Age (Yrs) Gender Site Histol. Type Prognosis Period (mos.) hTERT p38
65 Male thigh myxoid NED 93 4 0.4
35 Female popliteal myxoid CDF 108 31.6 1
50 Female thigh myxoid CDF 102 0 0.4
42 Male shoulder myxoid CDF 41 726.6 30.1
65 Male thigh myxoid CDF 56 484.9 38.2
66 Female thigh dediff. CDF 66 271.8 0.2
47 Female thigh myxoid CDF 84 117.5 21.1
58 Male thigh myxoid CDF 76 331.9 0.5
74 Male thigh myxoid DOD 27 148.7 11.2
60 Male thigh pleomorphic CDF 132 145 0.4
51 Male thigh pleomorphic CDF 31 3.1 1.4
66 Male upper arm myxoid CDF 70 29.5 0.7
69 Male thigh myxoid DOD 13 331.2 14
41 Male lower leg myxoid CDF 51 0.8 1.8
47 Male forearm dediff. DOD 12 435.8 2
62 Female thigh myxoid CDF 62 76.5 0.6
68 Male thigh myxoid CDF 100 97.5 1.1
73 Female buttock myxoid DOD 14 391.8 31.6
48 Female forearm myxoid CDF 132 0 1.9
52 Female thigh myxoid CDF 85 91.3 0
48 Male thigh myxoid DOD 15 94.3 0.7
60 Female thigh myxoid CDF 85 58.7 2
36 Male thigh myxoid CDF 81 46.8 0.9
56 Male thigh myxoid CDF 69 191.6 1.2
defiff. = dedifferentiated CDF = continuously disease-free
DOD = died of disease
Table 3 Data in 9 patients with bone MFH
Age (Yrs) Gender Site Histol. Type Prognosis Period (mos.) hTERT p38
23 Female femur stori-pleo CDF 130 304 0
65 Female femur stori-pleo DOD 37 1405.4 191.1
46 Male femur stori-pleo CDF 141 921.8 36.2
27 Female clavicle stori-pleo CDF 92 323.1 10.3
57 Male femur stori-pleo CDF 93 241.7 0
69 Male femur stori-pleo DOD 8 1278.2 60.3
67 Male sacrum stori-pleo DOD 7 324.5 35.2
38 Male humerus stori-pleo DOD 18 603.6 49.3
57 Female ilium stori-pleo DOD 6 326.5 35
stori-pleo = storiform-pleomorphic type
CDF = continuously disease-free
DOD = died of disease
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Patients who had a higher than average expression of
p38 MAPK (5-year survival rate: 0%) had a worse prog-
nosis than other patients (66.7%), but did not reach sig-
nificant differences (p = 0.202). There were no
significant differences in prognosis between patients
who had a higher than average expression of hTERT
(33.3%) and those who did not (50.0%) (p = 0.904).
Discussion
hTERT is the catalytic telomerase subunit component
that copies a template region of its functional RNA sub-
unit to the end of the telomere. In terms of carcinomas,
hTERT mRNA expression and telomerase activity are
closely associated, and quantification of hTERT mRNA
h a sb e e nr e p o r t e da sa na l t e r n a t i v et ot h em e a s u r eo f
telomerase activity [7,25,26]. Also, in sarcomas, the cor-
relation between telomerase activity and hTERT has
been reported [9,10,27]. However, in contrast, previous
reports maintained that hTERT expression does not
correlate to telomerase activity [12,23], and hTERT
mRNA expression was only studied in the absence of
detectable telomerase activity on sarcomas [8,12,27,28].
There is no clear understanding of the discordance
between hTERT and telomerase activity in sarcomas
[23,29]. Recently, the presence of telomerase activity and
alternative lengthening of telomeres (ALT) in several
sarcomas was examined extensively, and these studies
indicate a positive correlation between the telomere
maintenance mechanism and tumor aggressiveness in
several sarcoma types [29]. Furthermore, a positive cor-
relation between hTERT and tumor aggressiveness in
several sarcomas has been reported [8-14]. Therefore, it
could be necessary to analyze hTERT, in order to eluci-
date the telomere maintenance mechanisms and the
tumorigenesis of sarcomas.
T h ep r e d o m i n e n c eo fl a r g en u m b e r so fp r o t e i n
kinases involved in signal cascades following genotoxic
stress is the p38 MAPK [30]. p38 MAPK is shown to
induce a wide variety of intracellular responses, with
Figure 1 Correlation between p38 and hTERT in all samples. There was a significant correlation between the values of p38 expression and
those of hTERT, with increased p38 expression with higher hTERT in all samples (r = 0.445, p = 0.0001).
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ment, inflammation and apoptosis [15-17]. Recent stu-
dies have suggested that signals transmitted through
MAP kinase can regulate hTERT transcription. Epider-
mal growth factor (EGF) affects the up-regulation of
hTERT transcription through the MAP kinase cascades
[20]. E26 transformation-specific (Ets) transcription fac-
tors, downstream of the mitogen signaling pathways of
MAP kinase, regulates hTERT [31]. p38 MAPK may
play an important role in the activation of the hTERT
promoter by the upstream stimulatory factor (USF) in
tumor cells [32]. In the present study, there was a signif-
icant positive correlation between the values of p38
MAPK expression and hTERT, with increased p38
MAPK expression with higher hTERT in sarcoma sam-
ples. This is the first report to show a correlation
between the levels of hTERT mRNA expression and the
levels of p38 MAPK in human sarcomas, and these
results may suggest that p38 MAPK plays a role in up-
regulation of hTERT in soft tissue MFH, liposarcomas,
and bone MFH, while we do not have a clear under-
standing if some factor regulates both p38 MAPK and
hTERT expression.
Recent studies have demonstrated that p38 MAPK has
diverse roles in the pathogenesis of several cancers and
have shown that they are also involved in regulating
other functions including the differentiation and prolif-
eration of various cell types [33]. The p38 MAPK path-
way is most frequently associated with a tumor
suppressor function, based on its negative regulation of
proliferation and survival of cells [33,34]. However, con-
tradictory effects have been observed, a fact that points
to the pathway playing a positive role in cell-cycle pro-
gression in some carcinoma cells [35-37]. In terms of
sarcoma cells, inhibition of p38 MAPK activity rescues
the antitumor agent fenretinide-mediated cell death in
Ewing’s sarcoma family of tumors [38], and inhibition of
p38 signals results showing a significant reduction in
Figure 2 Kaplan-Meier analysis of the association between the survival and the p38 in all samples. Patients who had a higher than
average expression of p38 MAPK had a significantly worse prognosis (5-year survival rate; 38.1%) than other patients (73.8%) overall (p = 0.0036).
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Figure 3 Correlation between p38 and hTERT in soft tissue MFH samples. There was a significant correlation between the values of p38
expression and those of hTERT (r = 0.352, p = 0.0352).
Figure 4 Correlation between p38 and hTERT in liposarcoma samples. There was a significant correlation between the values of p38
expression and those of hTERT (r = 0.704, p = 0.0001).
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important role in tumorigenesis in these sarcomas. In
the clinical setting, p38 MAPK expression correlates to
poor prognosis (p = 0.0036) in overall patients; of high
expression of p38 MAPK, indicating the likelihood of a
poor outcome and may indicate a positive role of p38
MAPK in tumor proliferation and aggressiveness, in
patients with sarcomas. In terms of bone and soft tissue
MFH, there were no significant differences in prognosis
between patients who had a higher than average expres-
sion of p38 MAPK and those who did not. However,
patients who had above average p38 (5-year survival
rate: soft tissue MFH; 41.7%, bone MFH; 0%) had a
worse prognosis than other patients (5-year survival
rate: soft tissue MFH; 65.0%, bone MFH; 66.7%), but did
not reach significant differences. These results may be
due to small numbers of patients. Patients who had a
higher than average expression of p38 MAPK (5-year
survival rate: 50.0%) had a significantly worse prognosis
than other patients (88.9%) (p = 0.0448) in LS patients.
Therefore, high expression of p38 MAPK may correlate
with a worse prognosis especially for LS patients.
Conclusions
p38 MAPK may be a useful marker in the assessment of
hTERT and prognosis. Given that more than 80% of sar-
comas express p38 MAPK and hTERT, elucidation of
the pathways and target genes of p38 MAPK in
sarcomas will yield additional understandings into the
pathogenesis of several sarcomas and may lead to novel
therapeutic strategies for their treatment.
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